Creative Planning purchased a new position in shares of Tocagen Inc (NASDAQ:TOCA) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 10,734 shares of the company’s stock, valued at approximately $117,000.

Other large investors have also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. lifted its holdings in Tocagen by 162.8% during the 4th quarter. Meeder Asset Management Inc. now owns 9,961 shares of the company’s stock worth $82,000 after purchasing an additional 6,170 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in Tocagen by 9.0% in the 4th quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after acquiring an additional 949 shares in the last quarter. Caption Management LLC acquired a new position in Tocagen in the 4th quarter valued at $98,000. Bank of America Corp DE raised its holdings in Tocagen by 28.6% in the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after acquiring an additional 3,240 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Tocagen by 50.7% in the 4th quarter. Rhumbline Advisers now owns 23,303 shares of the company’s stock valued at $191,000 after acquiring an additional 7,843 shares in the last quarter. 36.58% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ TOCA opened at $8.85 on Thursday. The firm has a market capitalization of $212.36 million, a price-to-earnings ratio of -3.63 and a beta of 3.29. The company has a quick ratio of 5.05, a current ratio of 5.05 and a debt-to-equity ratio of 0.75. Tocagen Inc has a fifty-two week low of $6.47 and a fifty-two week high of $15.80.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.01. Tocagen had a negative return on equity of 108.08% and a negative net margin of 294.74%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $2.01 million. As a group, equities research analysts forecast that Tocagen Inc will post -3.05 EPS for the current fiscal year.

Several equities analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on Tocagen in a report on Thursday, April 25th. They issued an “overweight” rating and a $28.00 price objective for the company. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday. Leerink Swann assumed coverage on Tocagen in a report on Monday, April 15th. They issued a “market perform” rating and a $10.26 price objective for the company. Chardan Capital reaffirmed a “buy” rating on shares of Tocagen in a report on Tuesday, April 23rd. Finally, ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $18.78.

ILLEGAL ACTIVITY NOTICE: “Creative Planning Purchases New Holdings in Tocagen Inc (TOCA)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/creative-planning-purchases-new-holdings-in-tocagen-inc-toca/3011783.html.

Tocagen Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: What is an SEC Filing?

Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).

Institutional Ownership by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.